Last reviewed · How we verify
NCT04611204: PRATHYC
Transthyretin Cardiac Amyloidosis in Patients With Idiopathic Carpal Tunnel Syndrome Referred for Release Surgery
trial testing Descriptive cohort in Transthyretin Amyloidosis in 6 participants. Terminated before completion.
23 February 2023
Quick facts
| Lead sponsor | University Hospital, Toulouse |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 6 |
| Start date | 1 October 2020 |
| Primary completion | 23 February 2023 |
| Estimated completion | 23 February 2023 |
| Sites | 1 location across France |
Drugs / interventions tested
- Descriptive cohort
Conditions studied
- Transthyretin Amyloidosis — all drugs for Transthyretin Amyloidosis →
- Carpal Tunnel Syndrome — all drugs for Carpal Tunnel Syndrome →
Sponsor
University Hospital, Toulouse
Who can join
18 and older, any sex, with Transthyretin Amyloidosis or Carpal Tunnel Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will determine the prevalence of transthyretin amyloidosis in pathology of the transverse carpal ligament and cardiac involvement using natriuretic peptides, electrocardiography and echocardiography in patients referred for carpal tunnel release surgery of idiopathic carpal tunnel syndrome. This study will describe the relationship between amyloid deposition observed on the transverse carpal ligament and the presence of cardiac involvement.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04611204
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Transthyretin Amyloidosis
Currently open trials in the same condition.
- NCT07205666 — The Eplontersen Pregnancy and Lactation Outcomes Study · recruiting
- NCT06465810 — Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis · recruiting
- NCT06345235 — New Biomarkers and Plasma Prothrombotic Potential in Cardiac Transthyretin Amyloidosis · recruiting
- NCT05758493 — Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis · Phase 2 · recruiting
- NCT05023889 — Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy · EARLY_PHASE1 · active not recruiting
Other University Hospital, Toulouse trials
Trials by the same sponsor.
- NCT07497750 — Impact of Artificial Intelligence Algorithm-driven Versus Standard Lifestyle Intervention in Non-Alcoholic Fatty Liver D · NA · not yet recruiting
- NCT07507240 — The Benefits of a Care Pathway Combining Remote Monitoring and Support From a Nurse After a Change in Anti-epileptic Tre · NA · not yet recruiting
- NCT07524088 — Contamination of Young Children Hair During Acute Cannabis Intoxication · NA · not yet recruiting
- NCT07470580 — Radiofrequency Ablation Versus Adrenalectomy for Adenoma in Patients With Primary Aldosteronism and Hypertension · NA · not yet recruiting
- NCT07423988 — Evaluation of Changes in Sleep Efficiency Among PIC DU MIDI Staff Between Nights Spent at Home and Nights Spent in the W · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04611204 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Toulouse
- Last refreshed: 20 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04611204.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing